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The Editorial on the Research Topic
Bad Bugs in the XXIst Century: Resistance Mediated by Multi-Drug Eﬄux Pumps in
Gram-Negative Bacteria
The discovery of antibiotics represented a key milestone in the history of medicine. However, with
the rise of these life-saving drugs came the awareness that bacteria deploy defense mechanisms
to resist these antibiotics, and they are good at it. Today, we appear at a crossroads between
discovery of new potent drugs and omni-resistant superbugs. Moreover, the misuse of antibiotics
in different industries has increased the rate of resistance development by providing permanent
selective pressure and, subsequently, enrichment of multidrug resistant pathogens. As a result,
antimicrobial resistance has now become an urgent threat to public health worldwide (http://
www.who.int/drugresistance/documents/surveillancereport/en/). The development of multidrug
resistance (MDR) in an increasing number of pathogens, including Pseudomonas, Acinetobacter,
Klebsiella, Salmonella, Burkholderia, and other Gram-negative bacteria is a serious issue.Membrane
eﬄux pump complexes of the Resistance-Nodulation-Division (RND) superfamily play a key role
in the development of MDR in these bacteria. These pumps, together with other transporters,
contribute to intrinsic and acquired resistance of bacteria toward most, if not all, of the compounds
available in our antimicrobial arsenal. Given the enormous drug polyspecificity of MDR eﬄux
pumps, studies on their mechanism of action are extremely challenging, and this has negatively
impacted both on the development of new antibiotics that are able to evade these eﬄux pumps and
on the design of pump inhibitors. The collection of articles in this eBook, published as a Research
Topic in Frontiers in Microbiology, section of Antimicrobials, Resistance, and Chemotherapy,
aims to update the reader about the latest advances on the structure and function of RND eﬄux
transporters, their roles in the overall multidrug resistance phenotype of Gram-negative pathogens,
and on the strategies to inhibit their activities.
RND transporters reside in the inner membrane, and in Gram-negative bacteria they form
trans-envelope complexes together with periplasmic membrane fusion proteins (MFPs) and outer
membrane factors (OMFs). As tripartite entities, these macromolecular complexes are powerful
machines that expel multiple antibiotics across outer membranes. In recent years, much of the
research efforts have been focused on the structures of the RND, MFP, and the OMF components.
The assembly and disassembly of the tripartite eﬄux pump components is so crucial to their
physiological role in resistance, that much research effort has been directed toward both the
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elucidation of the structures and functional dynamics of
individual components and the in vivo and in vitro assembly
and function of the tripartite systems. X-ray crystallography
has provided an understanding of the molecular basis of
drug transport by RND-type eﬄux pumps. Yamaguchi et
al. stress critical points related to structure and function of
these tripartite pumps, including the lack of consensus on
the number of adaptor proteins and the molecular basis for
multidrug recognition by two voluminous promiscuous binding
pockets in the RND transporter, and they formulate a multisite-
drug-oscillation hypothesis to describe their activity. Substrate-
mediated conformational changes in RND eﬄux pumps are also
investigated in silico by Wang et al. The authors use molecular
dynamics simulations of AcrB in complex with substrates to
discover an intrinsic allostery in the transport mechanism
upon binding of a second substrate. Dreier and Ruggerone
analyze how subtle differences in the physicochemical features
of antibiotics belonging to the same family determine their
diverse susceptibility to eﬄux mechanisms. They highlight the
importance of combining different high-resolution techniques
to gain insights on substrate recognition patterns. Broutin and
co-workers (Monlezun et al.) focus on the outer membrane
channel OprM of Pseudomonas aeruginosa, investigating the
presence of N-terminal modifications. They present a new X-
ray structure solved in a new space group, making it possible
to model the N-terminal residue of OprM as a palmitoylated
cysteine.
Several factors are critical for the proper function of the
tripartite system: drug binding, interaction with MFPs and
OMFs, proton relay through the transmembrane domain, and
trimerization of the transporter. Regarding the latter process,
Wang et al. use AcrAB-TolC of Escherichia coli as model to
explore the mechanism of function recovery of the AcrBP223G
variant, which compromises AcrB trimerization and drastically
reduces the drug eﬄux activity. Their study highlights how
modulation of several critical factors can lead to the proper
functioning of the pump. Zgurskaya et al. further analyze
how the reaction cycles of transporters are coupled to the
assembly of the trans-envelope complexes. Using a combination
of biochemical, genetic and biophysical approaches, the authors
reconstruct the sequence of events leading to the assembly
of transenvelope drug eﬄux complexes, and characterize the
roles of periplasmic and outer membrane proteins in this
process. In particular, they propose that OMF recruitment is
triggered by binding of effectors (substrates) to MFP or MFP-
RND complexes. Bavro and co-workers investigate in detail
the architecture and roles of periplasmic adaptor proteins in
tripartite eﬄux pump assemblies (Symmons et al.). They stress
how recognition between the MFPs and OMFs is essential
for pump assembly and function, and how targeting this
interaction may provide a novel avenue for combating RND
pump-mediated multidrug resistance. Picard and co-workers
design a new test permitting investigation of the assembly of
the MexAB-OprM eﬄux system of P. aeruginosa with only
tens of microgram of protein (Ntsogo Enguene et al.). The
method relies on the streptavidin-mediated pull-down of OprM
proteoliposomes upon interaction with MexAB proteoliposomes
containing biotinylated lipids. Their study gives clear evidence
for the importance of MexA in promoting and stabilizing the
assembly of the MexAB-OprM complex and the role of the
protonmotive force on the assembly and disassembly of the eﬄux
pump.
Little of the in vitro work makes sense without
an understanding of the occurrence, regulation, and
interdependence of the eﬄux pumps in a physiological setting.
Martins and co-workers summarize the current knowledge on
RND eﬄux mechanisms in E. coli, a bacterium responsible
for community and hospital-acquired infections, as well as
foodborne outbreaks worldwide (Anes et al.). They review
the knowledge on Acriflavine (Acr), Multidrug Transport
(Mdt), and Copper transporting (Cus) eﬄux systems. Chen
and collaborators use clinical Salmonella typhimurium isolates
to demonstrate how acquisition of the plasmid-mediated
quinolone resistance (PMQR) genes oqxAB and aac(6′)Ib-cr
accelerates the development of fluoroquinolone resistance in
this bacterium (Wong et al.). Their analysis reveals that oqxAB
and aac(6′)Ib-cr are encoded on plasmids of various sizes
and mediate resistance to ciprofloxacin, ultimately facilitating
the selection of ciprofloxacin-resistant S. typhimurium. In
their Perspective, Paulsen and collaborators summarize the
current knowledge on the Acinetobacter chlorhexidine eﬄux
(AceI) pump, a prototype for a novel family of multidrug
eﬄux pumps conserved in many proteobacterial lineages
(Hassan et al.). The discovery of this family raises the
possibility that additional undiscovered intrinsic resistance
proteins may be encoded in the core genomes of pathogenic
bacteria.
Among the mechanisms that are not fully understood is
the genetic regulation of eﬄux pumps. Morita and co-workers
identify a novel MexS variant involved in up-regulation of the
mexEF-oprN multidrug eﬄux operon in a clinical isolate of
P. aeruginosa displaying multi-drug eﬄux-mediated resistance
to fluoroquinolones, aminoglycosides, and most β-lactams.
Their study constitutes the first genetic evidence that a MexS
variant causesmexEF-oprN upregulation in P. aeruginosa clinical
isolates. If the road toward understanding of eﬄux-mediated
multi-drug resistance in E. coli, Acinetobacter baumannii and
P. aeruginosa is rough, the characterization of eﬄux pumps in
many other prominent pathogens, e.g., the members of the genus
Burkholderia, lags even further behind. As in other non-enteric
Gram-negatives, eﬄux pumps of the resistance nodulation cell
division (RND) family are the clinically the most significant
eﬄux systems in this genus. Schweizer and co-workers provide
an excellent review of the current knowledge about eﬄux
mechanisms in several Burkholderia species (Podnecky et al.).
Last but not least, inhibition of eﬄux pumps is one of the
current strategies being pursued by several groups attempting to
reduce the impact of eﬄux on antimicrobial resistance. Eﬄux
pump inhibitors (EPIs) could be used as adjunctive therapies
that would increase the potency of existing antibiotics and
decrease the emergence of multidrug-resistant bacteria. In their
review, Venter et al. describe how available biochemical and
structural information can be translated into the discovery and
development of new compounds that could reverse antimicrobial
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resistance in Gram-negative pathogens. Opperman and Nguyen
analyze in detail the reasons why no compounds have yet
progressed into clinical use. One of the major hurdles in
the development of EPIs has been the lack of biochemical,
computational, and structural methods that could be used to
guide rational drug design. The authors review recent reports that
have advanced our understanding of the mechanisms of action of
several potent EPIs active against RND-type pumps.
In summary, the articles in this research topic serve as
a background to the search for a deeper understanding
of the mechanisms by which RND eﬄux pumps limit
the concentration of antimicrobial compounds inside the
bacterial cell. This knowledge may in turn pave the way
for new, more directed inhibitor and antibiotic design to
ultimately overcome antimicrobial resistance in Gram-negative
pathogens.
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